Page 1

Alcon MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG • • • • Alcon Reports Third Quarter 2021 Results Third quarter sales of $ 2.1 billion , up 15 % or 14 % constant currency Continued growth in all Surgical and Vision Care categories versus 2020 , driven by innovation , commercial execution and market recovery Nine months cash from operations of $ 958 million and free cash flow of $ 578 million Expanding in surgical glaucoma with intended acquisition of Ivantis Ad Hoc Announcement Pursuant to Art . 53 LR Geneva , November 9 , 2021 - Alcon ( SIX / NYSE : ALC ) , the global leader in eye care , reported its financial results for the three and nine months ended September 30 , 2021. For the third quarter of 2021 , worldwide sales were $ 2.1 billion , an increase of 15 % on a reported basis and 14 % on a constant currency basis ( 2 ) , as compared to the same quarter of the previous year . Third quarter 2021 diluted earnings per share were $ 0.00 and core diluted earnings per share were $ 0.54 . Third quarter and nine months 2021 key figures Net sales ( $ millions ) Operating margin ( % ) Core operating margin ( % ) ( ¹ ) Diluted earnings / ( loss ) per share ( $ ) Core diluted earnings per share ( $ ) ( 1 ) Three months ended September 30 Nine months ended September 30 2021 2020 2021 2020 2,084 1,818 6,088 4,838 1.0 % ( 7.1 ) % 6.5 % ( 12.9 ) % 17.7 % 15.3 % 18.0 % 10.4 % 0.00 ( 0.30 ) 0.48 ( 1.28 ) 0.54 0.39 1.60 0.63 " Our third quarter performance demonstrates the strength of Alcon's product pipeline , innovation and commercial execution , resulting in continued growth in all Surgical and Vision Care sales categories , " said David Endicott , Alcon's Chief Executive Officer . Mr. Endicott continued , " We are developing and delivering differentiated products , platforms and services that enhance eye care around the world . In Surgical , we are building on our leadership by creating an ecosystem that connects and integrates data systems and equipment in the clinic and operating room . We are also excited to expand our presence in the fast - growing surgical glaucoma market with our intended acquisition of Ivantis . In Vision Care , we are adding new SiHy contact lens designs for daily and reusable wearers , as well as expanding our Systane family with multi - dose preservative - free formulations . " 1